Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

Vaccine

Volumn 22, Issue 21-22, 2004, Pages 2936-2942

  Brown, Darron R ^a   Fife, Kenneth H ^a   Wheeler, Cosette M ^b   Koutsky, Laura A ^c   Lupinacci, Lisa M ^d   Railkar, Radha ^d   Suhr, Gretchen ^d   Barr, Eliav ^d   Dicello, Anthony ^d   Li, Weili ^d   Smith, Judith F ^d   Tadesse, Amha ^d   Jansen, Kathrin U ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Human papillomavirus; Polymerase chain reaction; Vaccination; Virus like particle

Indexed keywords

HUMAN PAPILLOMAVIRUS TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; PAIN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; VACCINATION; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECIMEN HANDLING; TIME FACTORS; VACCINES, DNA; VIRAL VACCINES;

EID: 3142568679     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.059     Document Type: Article

References (21)

1. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. JNCI. 87:1995;796-802
2. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
3. Moscicki A.B., Hills N., Shiboski S., Powell K., Jay N., Hanson E., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 286:2001;1173-1174
4. Nobbenhuis M.A.E., Walboomers J.M.M., Helmerhorst T.J.M., Rozendaal L., Remmink A.J., Risse E.K.J., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 354:1999;20-25
5. Ho G.Y.F., Burk R.D., Klein S., Kadish A.S., Chang C.J., Palan P. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. JNCI. 87:1995;1365-1371
6. Wallin K.L., Wiklund F., Ångström T., Bergman F., Stendahl U., Wadell G., et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. NEJM. 341:1999;1633-1638
7. Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H. Expression of vaccinia recombinant HPV16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 185:1991;251-257
8. Hagensee M.E., Yaegashi N., Galloway D.A. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67:1993;315-322
9. Hagensee M.E., Galloway D.A. Growing human papillomaviruses and virus-like particles in the laboratory. Papillomavirus Rep. 4:1993;121-124
10. Rose R.C., Bonnez W., Reichman R.C., Garcea R.L. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J. Virol. 67:1993;1936-1944
11. Neeper M.P., Hofmann K.J., Jansen K.U. Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae. Gene. 180:1996;1-6
12. Christensen N.D., Reed C.A., Cladel N.M., Hall K., Leiserowitz G.S. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology. 224:1996;477-486
13. Jansen K.U., Rosolowsky M., Schultz L.D., Markus H.Z., Cook J.C., Donnelly J.J., et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine. 13:1995;1509-1514
14. Bryan J.T., Jansen K.U., Lowe R.S., Fife K.H., McClowry T., Glass D., et al. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle IgG concentration. J. Med. Virol. 53:1997;185-188
15. Brown D., Bryan J., Schroeder J., Robinson T., Fife K., Wheeler C., et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. JID. 184:2001;1183-1186
16. Lin Y.L., Borenstein L.A., Ahmed R., Wettstein F.O. Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product. J. Virol. 67:1993;4154-4162
17. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. PNAS. 92:1995;11553-11557
18. Harro C., Pang Y., Roden R., Hildesheim A., Wang Z., Reynolds M., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:2001;252-253
19. Koutsky L., Ault K., Wheeler C., Brown D., Barr E., Alvarez F. Randomized clinical trial of human papillomavirus type 16 vaccine. NEJM. 347:2002;1645-1651
20. Lowe R.S., Brown D.R., Bryan J.T., Cook J.C., George H.A., Hofmann K.J., et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. JID. 176:1997;1141-1145
21. Chan I.S.F., Bodihar N.R. Exact power and sample size for vaccine efficacy studies. Commun. Stat. Theory Methods. 27:1998;1305-1322